Conor Hanley Sells 5,694 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Director Conor Hanley sold 5,694 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $25.25, for a total transaction of $143,773.50. Following the completion of the transaction, the director owned 6,272 shares in the company, valued at approximately $158,368. The trade was a 47.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Performance

Shares of Kestra Medical Technologies stock opened at $22.85 on Friday. The business has a 50-day moving average price of $25.34 and a two-hundred day moving average price of $22.71. Kestra Medical Technologies, Ltd. has a 1-year low of $17.34 and a 1-year high of $30.00. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The company has a market cap of $1.34 billion, a P/E ratio of -9.44 and a beta of 0.62.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The business had revenue of $28.64 million for the quarter. As a group, analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

More Kestra Medical Technologies News

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Kestra appointed Daniel Finney as Vice President of Research & Development and added him to its executive leadership team. Finney has more than 20 years of Class III medical-device experience and previously led Kestra’s new product development. He will oversee innovation for the Cardiac Recovery System, including strategic partnerships and artificial-intelligence initiatives, providing leadership continuity after the retirement of Phillip Foshee. Kestra Names Daniel Finney Vice President of Research & Development
• Neutral Sentiment: Reported short interest was zero shares as of September 10, unchanged from the prior reporting period. This suggests limited measurable short-selling pressure, but also provides little new information for investors.
• Neutral Sentiment: Analyst expectations remain mixed. BTIG maintains a $32 price target and JPMorgan has a $30 target, while other analysts are more cautious; the reported median target from recent forecasts is $24.50. The upcoming earnings release could prompt additional estimate changes. Kestra earnings preview
• Negative Sentiment: Four directors sold a combined 16,424 shares worth approximately $414,000. The transactions reduced their individual holdings by about 9% to 48%. Because the sales were made to cover tax withholding on vested equity awards, they are less concerning than discretionary selling, though the cluster may weigh on sentiment. SEC insider transaction filings
• Negative Sentiment: Kestra is expected to report a first-quarter loss, adding to concerns about profitability. Its latest reported quarter showed a $0.67 per-share loss, worse than the $0.59 consensus estimate, despite revenue of $28.64 million. Analysts currently forecast a full-year loss of approximately $2.29 per share.

Analyst Ratings Changes

Several research analysts recently issued reports on KMTS shares. Wall Street Zen lowered shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday. BTIG Research reiterated a “buy” rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a report on Wednesday, September 2nd. JPMorgan Chase & Co. initiated coverage on shares of Kestra Medical Technologies in a research report on Monday, August 10th. They set an “overweight” rating and a $30.00 price objective on the stock. Oppenheimer assumed coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating for the company. Finally, Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a research note on Wednesday, July 15th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.14.

Hedge Funds Weigh In On Kestra Medical Technologies

A number of hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD lifted its holdings in shares of Kestra Medical Technologies by 137.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock valued at $115,878,000 after purchasing an additional 2,529,851 shares in the last quarter. California State Teachers Retirement System grew its holdings in Kestra Medical Technologies by 2,366.0% during the second quarter. California State Teachers Retirement System now owns 686,422 shares of the company’s stock worth $17,463,000 after buying an additional 658,587 shares in the last quarter. Franklin Resources Inc. raised its position in Kestra Medical Technologies by 180.8% in the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after buying an additional 612,343 shares during the last quarter. Millennium Management LLC bought a new position in Kestra Medical Technologies during the 1st quarter valued at $11,036,000. Finally, Brown Advisory Inc. lifted its stake in Kestra Medical Technologies by 34.1% during the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after acquiring an additional 428,996 shares in the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.